http://www.pharmaceutical-business-review.com Latest news from Pharmaceutical Business Review en-us Copyright 2006, Datamonitor Thu, 16 Nov 2006 17:31:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=839DE890-A62B-4B3C-BB05-77EFFB5A2924 Indian company Advinus Therapeutics has signed a deal with Merck & Co. to jointly develop two metabolic drugs. Thu, 16 Nov 2006 17:31:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=F7B98B36-1B9B-45F2-8EEE-DE91346015D2 New research performed at Washington University School of Medicine has revealed the mechanisms that contribute to liver disease in alpha-1-AT deficiency patients. Thu, 16 Nov 2006 17:30:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=18E758BD-866D-409B-AFEA-EC67D1ACC61C In the latest court case relating to Merck & Co.'s drug Vioxx, a jury has rejected the claim that the painkiller caused the heart attack of a 61-year-old man. Thu, 16 Nov 2006 17:29:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=102413B1-60CA-4987-A0D6-ECD247EC14F4 Pharmion Corporation has purchased private oncology company Cabrellis, which holds the US and EU rights to lung cancer drug amrubicin, for $59 million. Thu, 16 Nov 2006 17:29:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=6AA5762D-0692-43D7-8110-AC4B848FF090 A new analysis of Pfizer's best selling heart drug Lipitor has shown that patients with chronic kidney disease reduced their risk of heart attack, particularly when taking the drug at higher doses. Thu, 16 Nov 2006 17:28:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=4716E53F-DD79-4EA7-ACBF-97183566FC6E UK pharmaceutical company AstraZeneca has released new data from a study which demonstrated that Crestor induced regression of atherosclerosis which may improve diseased arteries. Thu, 16 Nov 2006 17:26:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=45CCC499-2A82-4DDF-8339-4CBA7A8E4A05 MethylGene and its collaborator EnVivo Pharmaceuticals have entered into an agreement with the non-profit organization CHDI, to discover and develop treatments for Huntington's disease. Thu, 16 Nov 2006 17:26:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=3121B796-8E7E-499A-929D-C8A0C88A9960 Sonus Pharmaceuticals has completed enrollment in the phase III trial of its oncology product candidate, Tocosol Paclitaxel, in women with metastatic breast cancer. Thu, 16 Nov 2006 17:25:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=30688FA3-5728-4171-956C-EEF6F6EF10E7 Aegerion Pharmaceuticals has reported interim results from its ongoing phase II trial involving its lead cholesterol management compound, AEGR-733, alone and in combination with Zetia. Thu, 16 Nov 2006 17:24:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=C47F089D-3A2E-4683-A8CE-11A3C40973BD Merck & Co.'s investigational compound MK-0524 reduced flushing in patients with dyslipidemia when combined with extended release niacin according to phase II study data. Thu, 16 Nov 2006 09:39:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=0F40531B-6B21-4D7E-8C43-06B639421CED Reata Pharmaceuticals has presented preclinical data showing that its investigatonal drug candidate RTA 402 prevented the development of lung cancer in a mouse model of the disease. Thu, 16 Nov 2006 09:31:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=7C6B3D41-6860-4EFC-8544-D3E053763928 New data presented by Alteon suggests its compound ALT-2074 reduces myocardial injury in mice with diabetes by over 80%. Thu, 16 Nov 2006 09:22:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=CC546C06-1BA7-4878-A414-4E33576AF94D Synta Pharmaceuticals has said its oncology drug candidate, STA-4783, has been granted fast track designation by the FDA for the treatment of metastatic melanoma, a serious type of skin cancer. Thu, 16 Nov 2006 05:28:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=25BD9D81-BB8F-4074-837A-8A07A0DA7379 Ambrilia Biopharma has entered into a licensing and distribution agreement with Teva Europe for the marketing of its improved sustained-release formulation of octreotide for the treatment of acromegaly. Thu, 16 Nov 2006 05:25:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=354FC61D-F25F-41DC-952C-343699457C10 Novalar Pharmaceuticals has said that NV-101, a local dental anesthetic reversal agent, met its safety and efficacy endpoints in a phase II study for pediatric patients. Thu, 16 Nov 2006 05:19:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=188DD6BA-DCBA-4F30-921B-FD5408AB6138 British researchers have developed a vaccine that stimulates colorectal cancer patients' immune systems to fight cancerous cells. Thu, 16 Nov 2006 05:18:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=41A6A2FC-787A-4E6A-8121-BB5ED01E0A61 Cobalt Laboratories has settled patent litigation with GlaxoSmithKline relating to sumatriptan succinate tablets, the generic version of GSK's Imitrex tablets. Thu, 16 Nov 2006 04:27:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=3F0FFA63-228D-4D38-983D-D81BAD080DB2 The Food and Drug Administration is planning to review the Sanofi-Aventis drug Ketek after reports that it could cause liver failure. Thu, 16 Nov 2006 04:24:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=A842532D-D6B0-47F5-9562-22FAF18EAA68 Vanda Pharmaceuticals has reported positive results from a phase III clinical trial evaluating VEC-162 in transient insomnia. Thu, 16 Nov 2006 04:24:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=AC91650B-1E5C-4C16-9EE5-831055940E44 Helix BioPharma has finished a phase II clinical study of topical interferon alpha-2b in women with lesions that are positive for the human papilloma virus infection. Thu, 16 Nov 2006 04:18:00 GMT